Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyondNina Prokoph, Suzanne D. Turner|Cancers|2018Cited by 86
Cell of Origin and Immunologic Events in the Pathogenesis of Breast Implant–Associated Anaplastic Large-Cell LymphomaSuzanne D. Turner, Marshall E. Kadin|American Journal Of Pathology|2019Cited by 54
The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN statusRicky M. Trigg, Suzanne D. Turner|Nature Communications|2019Cited by 42
Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastomaPerla Pucci, Suzanne D. Turner|Nature Communications|2024Cited by 14
Aberrant Anaplastic Lymphoma Kinase Activity Induces a p53 and Rb-Dependent Senescence-Like Arrest in the Absence of Detectable p53 StabilizationFiona Kate Elizabeth McDuff, Suzanne D. Turner|PLoS ONE|2011Cited by 4